Aspire Private Capital LLC Raises Stock Position in Boston Scientific Co. (NYSE:BSX)

Aspire Private Capital LLC grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 2.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,132 shares of the medical equipment provider’s stock after purchasing an additional 319 shares during the quarter. Aspire Private Capital LLC’s holdings in Boston Scientific were worth $1,084,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in BSX. Atomi Financial Group Inc. grew its holdings in Boston Scientific by 16.5% during the fourth quarter. Atomi Financial Group Inc. now owns 9,631 shares of the medical equipment provider’s stock valued at $860,000 after purchasing an additional 1,365 shares during the period. Clear Harbor Asset Management LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $251,000. Ballentine Partners LLC increased its holdings in Boston Scientific by 7.6% in the 4th quarter. Ballentine Partners LLC now owns 31,636 shares of the medical equipment provider’s stock worth $2,826,000 after acquiring an additional 2,248 shares in the last quarter. ZWJ Investment Counsel Inc. raised its stake in Boston Scientific by 0.3% during the 4th quarter. ZWJ Investment Counsel Inc. now owns 617,304 shares of the medical equipment provider’s stock worth $55,138,000 after acquiring an additional 1,761 shares during the period. Finally, Priebe Wealth Holdings LLC boosted its position in shares of Boston Scientific by 4.9% in the fourth quarter. Priebe Wealth Holdings LLC now owns 3,255 shares of the medical equipment provider’s stock worth $291,000 after purchasing an additional 152 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

BSX stock opened at $100.90 on Wednesday. The business has a 50-day moving average price of $91.21 and a 200 day moving average price of $84.76. Boston Scientific Co. has a 1-year low of $59.85 and a 1-year high of $101.14. The company has a market capitalization of $148.71 billion, a P/E ratio of 83.39, a PEG ratio of 2.59 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. Boston Scientific’s revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.50 earnings per share. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares of the company’s stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the sale, the executive vice president now directly owns 29,308 shares in the company, valued at approximately $2,660,580.24. The trade was a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,989 shares of company stock valued at $2,702,261. 0.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of analyst reports. Canaccord Genuity Group lifted their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Sanford C. Bernstein lifted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Wells Fargo & Company increased their price target on Boston Scientific from $98.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. BTIG Research lifted their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Bank of America increased their target price on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Three analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $97.26.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.